Brief: Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat
06/01/2026 14:03
Jan 6 (Reuters) - Akebia Therapeutics Inc AKBA.O: AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF PRALICIGUAT FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) Source text: ID:nGNX5NP1xm Further company coverage: AKBA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule